Skip to Main Content
Table 3.

Adjusted RRs and 95% CIs of incident subtype hematopoietic cancers according to aspartame intake levels derived from aspartame-containing beverages, the NIH-AARP Diet and Health Study, 1995-2000 (n = 473,984)

Aspartame intake (mg/d)Lymphoid malignancies*,
Non–lymphoid leukemia*,
Hodgkin lymphoma
Multiple myeloma
Non–Hodgkin lymphoma
Case, N = 279
RR (95% CI)
Case, N = 57RR (95% CI)Case, N = 273RR (95% CI)Overall
Small lymphocytic lymphoma and chronic lymphocytic leukemia
Immunoblastic lymphoma and lymphoblastic lymphoma/leukemia
Case, N = 1,279RR (95% CI)Case, N = 241RR (95% CI)Case, N = 45RR (95% CI)
None 29 1.00 (—) 127 1.00 (—) 592 1.00 (—) 109 1.00 (—) 23 1.00 (—) 121 1.00 (—) 
>0, <100 28 0.77 (0.44-1.32) 57 0.85 (0.62-1.17) 300 0.93 (0.81-1.07) 60 1.03 (0.75-1.41) 22 0.77 (0.42-1.42) 62 0.93 (0.68-1.27) 
≥100, <200   48 1.39 (0.99-1.96) 177 1.01 (0.85-1.19) 36 1.16 (0.79-1.71)   47 1.31 (0.93-1.85) 
≥200, <400   20 1.13 (0.70-1.83) 92 0.98 (0.78-1.22) 36 1.02 (0.69-1.52)   20 1.05 (0.65-1.70) 
≥400, <600   21 1.03 (0.64-1.66) 73 1.06 (0.82-1.35)     29 1.25 (0.82-1.91) 
≥600     45 0.95 (0.70-1.29)       
P for trend  0.34  0.40  0.91  0.84  0.40  0.19 
Aspartame intake (mg/d)Lymphoid malignancies*,
Non–lymphoid leukemia*,
Hodgkin lymphoma
Multiple myeloma
Non–Hodgkin lymphoma
Case, N = 279
RR (95% CI)
Case, N = 57RR (95% CI)Case, N = 273RR (95% CI)Overall
Small lymphocytic lymphoma and chronic lymphocytic leukemia
Immunoblastic lymphoma and lymphoblastic lymphoma/leukemia
Case, N = 1,279RR (95% CI)Case, N = 241RR (95% CI)Case, N = 45RR (95% CI)
None 29 1.00 (—) 127 1.00 (—) 592 1.00 (—) 109 1.00 (—) 23 1.00 (—) 121 1.00 (—) 
>0, <100 28 0.77 (0.44-1.32) 57 0.85 (0.62-1.17) 300 0.93 (0.81-1.07) 60 1.03 (0.75-1.41) 22 0.77 (0.42-1.42) 62 0.93 (0.68-1.27) 
≥100, <200   48 1.39 (0.99-1.96) 177 1.01 (0.85-1.19) 36 1.16 (0.79-1.71)   47 1.31 (0.93-1.85) 
≥200, <400   20 1.13 (0.70-1.83) 92 0.98 (0.78-1.22) 36 1.02 (0.69-1.52)   20 1.05 (0.65-1.70) 
≥400, <600   21 1.03 (0.64-1.66) 73 1.06 (0.82-1.35)     29 1.25 (0.82-1.91) 
≥600     45 0.95 (0.70-1.29)       
P for trend  0.34  0.40  0.91  0.84  0.40  0.19 

NOTE: Cox proportional hazards regression model adjusted for age at entry (continuous), sex, and ethnicity (non–Hispanic White, non–Hispanic Black, others), BMI (weight in kilograms / height in meters squared; four categories of ≥18.5 and <25, ≥25 and <30, ≥30 and <35, and ≥35), and history of diabetes.

*

The aspartame-cancer associations are presented separately for lymphoid malignancies and non–lymphoid leukemias, then main lymphoid malignancies of Hodgkin lymphoma, multiple myeloma, and non-Hodgkin lymphoma. In addition, two subgroups within non-Hodgkin's lymphoma are presented: (a) small lymphocytic lymphoma and chronic lymphocytic leukemia and (b) immunoblastic lymphoma and lymphoblastic lymphoma/leukemia.

Due to small numbers, higher aspartame categories were collapsed for subtype cancers other than non-Hodgkin lymphoma.

Close Modal

or Create an Account

Close Modal
Close Modal